Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

Atezolizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Squamous Non-Small Cell Lung Cancer.

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Squamous Non-Small Cell Lung Cancer.

A small study of 18 patients with skin cancer found that the combination of vitamin D and chemotherapy provided an immune ...